Elicio Therapeutics

IN THE PRESS

Press Releases

Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

December 12, 2024

·

9 min read

Press Releases

Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

December 4, 2024

·

8 min read

Press Releases

Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 14, 2024

·

12 min read

Press Releases

Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

October 31, 2024

·

7 min read

Press Releases

Elicio Therapeutics Reports Inducement Grants

September 17, 2024

·

2 min read

Press Releases

Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines

September 16, 2024

·

7 min read

Press Releases

Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

August 28, 2024

·

1 min read

Business

Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

August 13, 2024

·

12 min read

Press Releases

Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note

August 13, 2024

·

5 min read

Genetown

Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting

May 23, 2024

·

9 min read

JOBS